Strategies for preventing immunologic rejection of transplanted human embryonic stem cells.

Human embryonic stem alls (hESC) have an unlimited capacity of proliferation and self-renewal resulting in a promise for future applications in regenerative medicine. One major problem derived from their use in cellular therapy protocols is the immunological rejection due to HLA incompatibility. Currently, there are four strategies to prevent allograft rejection of hESC; the development of a ''universal hESC line'' with lack of HLA class 1 expression; the creation of nuclear transfer hESC line; the development of hESC line banks; and the generation of haemopoietic chimerism.

[1]  R. Jaenisch,et al.  Mice lacking major histocompatibility complex class I and class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Murdoch,et al.  Derivation, growth and applications of human embryonic stem cells. , 2004, Reproduction.

[3]  Linzhao Cheng,et al.  Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro , 2004, The Lancet.

[4]  J. Hescheler,et al.  Embryonic stem cells: a promising tool for cell replacement therapy , 2004, Journal of cellular and molecular medicine.

[5]  F. Garrido,et al.  Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. , 2003, Tissue antigens.

[6]  D. Roopenian,et al.  Minor histocompatibility antigens. , 1997, Current opinion in immunology.

[7]  W R Mayr,et al.  Nomenclature for factors of the HLA system, 1998. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[8]  A. Svejgaard,et al.  Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. , 1995, Transplantation proceedings.

[9]  R. Zinkernagel,et al.  Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. , 2003, Transplantation.

[10]  D. Sachs,et al.  Tolerance to vascularized organ allografts in large-animal models. , 1999, Current opinion in immunology.

[11]  J. Morales.  Immunosuppressive treatment and progression of histologic lesions in kidney allografts. , 2005, Kidney international. Supplement.

[12]  K. Boheler,et al.  Embryonic stem cells: prospects for developmental biology and cell therapy. , 2005, Physiological reviews.

[13]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[14]  R. Pedersen,et al.  Stem cell medicine encounters the immune system , 2002, Nature Reviews Immunology.

[15]  Steven G.E. Marsh,et al.  Nomenclature for factors of the HLA system , 1975 .

[16]  L. Sharples,et al.  Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching , 2005, The Lancet.